Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Graciela Racaro Joins Signant Health as Chief Operating Officer
Signant Health, the leader in evidence generation for modern clinical trials, has announced the appointment […]
Labcorp Opens New Los Angeles Based Laboratory
Labcorp, a leading global life sciences company, has announced that it has begun operations at […]
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an […]
Stride Health Appoints Peter V. Lee, Former Executive Director of Covered California, to Board of Directors
Stride Health, the leader in portable benefits technology, announced the appointment of Peter V. Lee […]
Molecular Devices Acquires Cellesce, Expanding Industrywide Accessibility to Organoids
Molecular Devices, a leading provider of high-performance life science solutions, has announced the acquisition of […]
Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
Wellbeing Digital Sciences, an evidence-based mental healthcare company focused on the development and implementation of […]
AppliedVR Awarded Contract with VHA Innovation Ecosystem, a division of the United States Department of Veterans Affairs
AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel, virtual reality-based approach to medicine, has […]
Horizon Therapeutics Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Horizon Therapeutics has announced the first subject has been dosed in a Phase 1 randomized, […]
CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors
CDR-Life, a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics […]
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari, a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more